TherapeuticsMD Company Profile (NYSEMKT:TXMD)

About TherapeuticsMD (NYSEMKT:TXMD)

TherapeuticsMD logoTherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $1.04 billion
  • Outstanding Shares: 204,027,000
Average Prices:
  • 50 Day Moving Avg: $4.86
  • 200 Day Moving Avg: $4.86
  • 52 Week Range: $4.54 - $5.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.45
  • P/E Growth: -0.73
Sales & Book Value:
  • Annual Revenue: $18.26 million
  • Price / Sales: 56.98
  • Book Value: $0.46 per share
  • Price / Book: 11.09
Profitability:
  • EBITDA: ($88,990,000.00)
  • Net Margins: -462.94%
  • Return on Equity: -77.41%
  • Return on Assets: -68.24%
Misc:
  • Average Volume: 2.62 million shs.
  • Short Ratio: 24.24
 

Frequently Asked Questions for TherapeuticsMD (NYSEMKT:TXMD)

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NYSEMKT:TXMD) announced its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The company had revenue of $5.50 million for the quarter, compared to analysts' expectations of $5.76 million. TherapeuticsMD had a negative net margin of 462.94% and a negative return on equity of 77.41%. The company's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business earned ($0.11) earnings per share. View TherapeuticsMD's Earnings History.

Where is TherapeuticsMD's stock going? Where will TherapeuticsMD's stock price be in 2017?

7 brokerages have issued 1-year target prices for TherapeuticsMD's stock. Their forecasts range from $6.00 to $33.00. On average, they anticipate TherapeuticsMD's stock price to reach $18.93 in the next year. View Analyst Ratings for TherapeuticsMD.

Who are some of TherapeuticsMD's key competitors?

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:

  • Tommy G. Thompson J.D., Independent Chairman of the Board
  • John C. K. Milligan IV, President, Secretary, Director
  • Robert G. Finizio, Chief Executive Officer, Director
  • Daniel A. Cartwright, Chief Financial Officer, Treasurer
  • Mitchell L. Krassan, Executive Vice President, Chief Strategy Officer
  • Michael Donegan, Vice President - Finance
  • Brian Bernick M.D., Chief Clinical Officer, Director
  • Jules A. Musing, Director
  • J. Martin Carroll, Independent Director
  • Cooper C. Collins, Independent Director

How do I buy TherapeuticsMD stock?

Shares of TherapeuticsMD can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TherapeuticsMD stock can currently be purchased for approximately $5.10.


MarketBeat Community Rating for TherapeuticsMD (NYSEMKT TXMD)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  305
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for TherapeuticsMD (NYSEMKT:TXMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $18.93
Consensus Price Target History for TherapeuticsMD (NYSEMKT:TXMD)
Price Target History for TherapeuticsMD (NYSEMKT:TXMD)
Analysts' Ratings History for TherapeuticsMD (NYSEMKT:TXMD)
Show:
DateFirmActionRatingPrice TargetDetails
9/8/2017Morgan StanleyInitiated CoverageEqual Weight$6.00View Rating Details
7/11/2017Oppenheimer Holdings, Inc.UpgradeMarket Perform -> OutperformView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$20.00View Rating Details
5/11/2017Cantor FitzgeraldReiterated RatingOverweight$33.00View Rating Details
3/2/2017Jefferies Group LLCReiterated RatingBuy$18.00View Rating Details
12/6/2016GuggenheimReiterated RatingPositiveView Rating Details
12/4/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$10.50View Rating Details
7/11/2016Noble FinancialReiterated RatingBuy$17.50View Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for TherapeuticsMD (NYSEMKT:TXMD)
Earnings by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Earnings History by Quarter for TherapeuticsMD (NYSEMKT TXMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017Q416($0.12)($0.12)$5.91 million$4.49 millionViewListenView Earnings Details
11/3/2016Q316($0.11)($0.13)$5.76 million$5.50 millionViewN/AView Earnings Details
8/4/2016Q216($0.10)($0.11)$5.63 million$4.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.09)($0.11)$5.73 million$4.93 millionViewN/AView Earnings Details
2/25/2016Q415($0.10)($0.10)$5.33 million$5.63 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.11)$5.01 million$5.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.16)$4.65 million$4.80 millionViewListenView Earnings Details
5/5/2015($0.10)($0.13)ViewN/AView Earnings Details
3/10/2015Q414($0.09)($0.10)$2.86 million$4.26 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.08)($0.12)ViewN/AView Earnings Details
5/6/2014Q1 14($0.06)($0.06)$3.08 million$2.80 millionViewN/AView Earnings Details
3/3/2014Q213($0.06)($0.06)$2.72 million$2.90 millionViewN/AView Earnings Details
5/8/2013Q113($0.06)($0.06)$1.32 million$1.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TherapeuticsMD (NYSEMKT:TXMD)
Current Year EPS Consensus Estimate: $-0.44 EPS
Next Year EPS Consensus Estimate: $-0.33 EPS

Dividends

Dividend History for TherapeuticsMD (NYSEMKT:TXMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TherapeuticsMD (NYSEMKT:TXMD)
Insider Trades by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Institutional Ownership by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Insider Trades by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/11/2016Cooper C CollinsDirectorBuy16,000$6.23$99,680.00View SEC Filing  
8/25/2015Angus C RussellDirectorBuy13,500$5.98$80,730.00View SEC Filing  
6/8/2015Mitchell KrassanEVPSell30,000$8.18$245,400.00View SEC Filing  
5/12/2015Angus C RussellDirectorBuy35,000$6.15$215,250.00View SEC Filing  
5/11/2015Tommy G ThompsonChairmanBuy6,000$6.09$36,540.00View SEC Filing  
5/8/2015J Martin CarrollDirectorBuy10,000$6.11$61,100.00View SEC Filing  
11/21/2014Daniel A CartwrightCFOSell40,000$3.91$156,400.00View SEC Filing  
9/4/2014Tommy G ThompsonDirectorBuy1,757$5.44$9,558.08View SEC Filing  
6/5/2014Cooper C CollinsDirectorBuy20,000$3.84$76,800.00View SEC Filing  
5/9/2014Robert Lapenta, Jr.DirectorBuy5,000$3.66$18,300.00View SEC Filing  
5/8/2014Tommy ThompsonDirectorBuy14,000$3.57$49,980.00View SEC Filing  
3/26/2014Brian BernickDirectorSell421,268$6.70$2,822,495.60View SEC Filing  
3/26/2014John C.K. Iv MilliganInsiderSell353,412$6.70$2,367,860.40View SEC Filing  
3/26/2014Robert FinizioCEOSell982,053$6.70$6,579,755.10View SEC Filing  
3/10/2014Mitchell KrassanEVPSell7,500$7.73$57,975.00View SEC Filing  
2/26/2014John C.K. Iv MilliganPresidentSell25,000$6.31$157,750.00View SEC Filing  
2/21/2014Robert FinizioCEOSell50,000$6.17$308,500.00View SEC Filing  
2/12/2014Brian BernickDirectorSell31,250$6.16$192,500.00View SEC Filing  
1/30/2014John C.K. Iv MilliganInsiderSell25,000$6.16$154,000.00View SEC Filing  
1/23/2014Robert G FinizioCEOSell50,000$5.70$285,000.00View SEC Filing  
1/13/2014Mitchell KrassanEVPSell7,500$5.73$42,975.00View SEC Filing  
1/8/2014Brian BernickDirectorSell31,250$5.13$160,312.50View SEC Filing  
8/26/2013Brian BernickInsiderSell1,600,000$1.55$2,480,000.00View SEC Filing  
8/26/2013Jules A MusingDirectorBuy5,282$2.15$11,356.30View SEC Filing  
6/14/2013Cooper C CollinsDirectorSell2,631,579$1.75$4,605,263.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for TherapeuticsMD (NYSEMKT:TXMD)
Latest Headlines for TherapeuticsMD (NYSEMKT:TXMD)
Source:
DateHeadline
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - October 14 at 12:36 AM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 12 at 8:08 AM
finance.yahoo.com logoTherapeuticsMD CEO on the switch to Nasdaq from NYSE
finance.yahoo.com - October 10 at 7:47 AM
finance.yahoo.com logoETFs with exposure to TherapeuticsMD, Inc. : October 9, 2017
finance.yahoo.com - October 10 at 7:47 AM
finance.yahoo.com logoTherapeuticsMD Announces Pricing of Common Stock Offering
finance.yahoo.com - September 29 at 12:25 PM
finance.yahoo.com logoTherapeuticsMD, FDA Review for TX-004HR is Upcoming, Stock Shows Momentum
finance.yahoo.com - September 19 at 8:56 AM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 17 at 8:40 AM
streetinsider.com logoTherapeuticsMD (TXMD) Submits Additional Endometrial Safety Information to NDA for TX-004HR - StreetInsider.com
www.streetinsider.com - September 15 at 10:31 AM
finance.yahoo.com logoTherapeuticsMD Announces Submission of Additional Endometrial Safety Information to the New Drug Application for TX-004HR
finance.yahoo.com - September 15 at 10:31 AM
finance.yahoo.com logoOptions Traders Expect Huge Moves in TherapeuticsMD (TXMD) Stock
finance.yahoo.com - September 14 at 11:52 AM
finance.yahoo.com logoOptions Traders Expect Huge Moves in TherapeuticsMD (TXMD) Stock
finance.yahoo.com - September 14 at 11:52 AM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Receives New Coverage from Analysts at Morgan Stanley
www.americanbankingnews.com - September 8 at 1:16 PM
prnewswire.com logoTechnical Reports on Drug Makers Equities -- Impax Labs, GlaxoSmithKline, Novartis, and TherapeuticsMD
www.prnewswire.com - August 29 at 9:08 AM
finance.yahoo.com logoImplied Volatility Surging for TherapeuticsMD, Inc. (TXMD) Stock Options
finance.yahoo.com - August 23 at 1:07 PM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 23 at 8:37 AM
nasdaq.com logoTherapeuticsMD (TXMD) Catches Eye: Stock Moves 5.9% Higher - Nasdaq
www.nasdaq.com - August 20 at 1:23 PM
finance.yahoo.com logoTherapeuticsMD (TXMD) Catches Eye: Stock Moves 5.9% Higher - Yahoo Finance
finance.yahoo.com - August 19 at 8:33 AM
zacks.com logoTherapeuticsMD (TXMD) Catches Eye: Stock Moves 5.9% Higher
www.zacks.com - August 18 at 8:13 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: TherapeuticsMD Inc. and Horizon Pharma
finance.yahoo.com - August 18 at 8:13 AM
streetinsider.com logoTherapeuticsMD (TXMD) Reports Publication of Manuscript on Women's Health Initiative Observational Study of ... - StreetInsider.com
www.streetinsider.com - August 17 at 8:46 AM
finance.yahoo.com logoTherapeuticsMD Announces Publication of Manuscript on the Women’s Health Initiative Observational Study of Vaginal Estrogen Use in Postmenopausal Women
finance.yahoo.com - August 17 at 8:45 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about TherapeuticsMD Inc.
finance.yahoo.com - August 14 at 8:01 AM
streetinsider.com logoTherapeuticsMD (TXMD) Issue Update on TX-004HR, Says FDA ... - StreetInsider.com
www.streetinsider.com - August 11 at 9:04 AM
streetinsider.com logoTherapeuticsMD (TXMD) Issue Update on TX-004HR, Says FDA Requested Additional Info on or Before Sept. 18, Tentative Meeting Set for Nov. 3
www.streetinsider.com - August 11 at 9:04 AM
finance.yahoo.com logoIHS Markit Score Update: Drop in demand for ETFs holding TherapeuticsMD Inc is a negative sign for its shares
finance.yahoo.com - August 10 at 9:04 AM
finance.yahoo.com logoEdited Transcript of TXMD earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 5 at 8:02 AM
finance.yahoo.com logoInvestor Network: TherapeuticsMD, Inc. to Host Earnings Call
finance.yahoo.com - August 4 at 9:27 AM
finance.yahoo.com logoTherapeuticsMD Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 4 at 9:27 AM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 29 at 8:39 AM
finance.yahoo.com logoETFs with exposure to TherapeuticsMD, Inc. : July 25, 2017
finance.yahoo.com - July 26 at 9:20 AM
finance.yahoo.com logoTherapeuticsMD to Host Second Quarter Financial Results Conference Call and Webcast on August 3
finance.yahoo.com - July 21 at 8:12 AM
prnewswire.com logoTechnical Reports on Drug Makers Equities -- TherapeuticsMD, GlaxoSmithKline, Novartis, and Impax Labs
www.prnewswire.com - July 20 at 9:13 AM
finance.yahoo.com logoCantor Remains Bullish on TherapeuticsMD Inc (TXMD) as Investors Await Clarity on TX-004
finance.yahoo.com - July 18 at 9:23 AM
benzinga.com logo20 Stocks Moving In Monday's Pre-Market Session - Benzinga
www.benzinga.com - July 17 at 9:14 AM
streetinsider.com logoTherapeuticsMD (TXMD) Announces Regulatory Update Regarding NDA for TX-004HR - StreetInsider.com
www.streetinsider.com - July 17 at 9:14 AM
finance.yahoo.com logoETFs with exposure to TherapeuticsMD, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 9:31 PM
finance.yahoo.com logoWhy TherapeuticsMD Inc Is Soaring Today
finance.yahoo.com - July 12 at 8:31 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: TherapeuticsMD, Inc. and Moleculin Biotech, Inc.
finance.yahoo.com - July 12 at 8:31 AM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Raised to "Outperform" at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 11 at 1:46 PM
nasdaq.com logoBurns J W & Co Inc Buys Amgen Inc, SPDR S&P Dividend, Vanguard REIT ETF - DNQ, Sells ...
www.nasdaq.com - July 8 at 3:01 PM
finance.yahoo.com logoTherapeuticsMD, Inc. breached its 50 day moving average in a Bearish Manner : TXMD-US : July 7, 2017
finance.yahoo.com - July 8 at 3:01 PM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 4 at 8:16 AM
prnewswire.com logoStocks Under Scanner in the Drug Makers Space -- TherapeuticsMD ...
www.prnewswire.com - June 17 at 6:55 AM
prnewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ... - PR Newswire (press release)
www.prnewswire.com - June 17 at 6:55 AM
globenewswire.com logoIMPORTANT THERAPEUTICSMD, INC. INVESTOR REMINDER: Wolf Haldenstein Adler ...
globenewswire.com - May 26 at 8:04 AM
prnewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TherapeuticsMD, Inc ... - PR Newswire (press release)
www.prnewswire.com - May 11 at 2:35 AM
fool.com logoHere's Why TherapeuticsMD Inc. Stock Is Sinking Today - Motley Fool
www.fool.com - May 9 at 7:54 PM
fool.com logoHere's Why TherapeuticsMD Inc. Stock Is Sinking Today
www.fool.com - May 8 at 1:43 PM
streetinsider.com logoTherapeuticsMD (TXMD) Receives CRL from FDA for TX-004HR NDA - StreetInsider.com
www.streetinsider.com - May 8 at 9:33 AM
nasdaq.com logoTXMD All Set For D-day, IMMU Soars On Strategic Plan, CTSO On Watch - Nasdaq
www.nasdaq.com - May 7 at 9:56 PM

Social

Chart

TherapeuticsMD (TXMD) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.